News
SGHT
8.26
-1.55%
-0.13
Weekly Report: what happened at SGHT last week (1005-1009)?
Weekly Report · 2d ago
Sight Sciences: Signs Of Progress, But Plenty Of Work Remains
Seeking Alpha · 4d ago
Have Sight Sciences Insiders Been Selling Stock?
Simply Wall St · 6d ago
Strong Buy at under $10: The highest Quant-rated bargain stocks right now
Seeking Alpha · 10/07 11:38
Sight Sciences Price Target Raised to $10.00/Share From $8.00 by Citigroup
Dow Jones · 10/06 20:44
Sight Sciences Is Maintained at Neutral by Citigroup
Dow Jones · 10/06 20:44
Citi ups Sight Sciences target, opens ‘upside 90-day catalyst watch’
TipRanks · 10/05 11:06
Weekly Report: what happened at SGHT last week (0928-1002)?
Weekly Report · 10/05 10:29
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
Barchart · 10/01 06:05
Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT
NASDAQ · 09/30 10:14
Weekly Report: what happened at SGHT last week (0921-0925)?
Weekly Report · 09/28 10:24
Weekly Report: what happened at SGHT last week (0914-0918)?
Weekly Report · 09/21 10:24
Weekly Report: what happened at SGHT last week (0907-0911)?
Weekly Report · 09/14 10:30
Weekly Report: what happened at SGHT last week (0831-0904)?
Weekly Report · 09/07 10:23
Weekly Report: what happened at SGHT last week (0824-0828)?
Weekly Report · 08/31 10:31
Weekly Report: what happened at SGHT last week (0817-0821)?
Weekly Report · 08/24 10:31
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Moderna (MRNA), Merck & Company (MRK) and Sight Sciences (SGHT)
TipRanks · 08/19 13:30
Sight Sciences' TearCare Becomes First FDA-Approved MGD Therapy For Dry Eye Disease; Stock Up
NASDAQ · 08/19 12:29
Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy
NASDAQ · 08/19 11:50
Sight Sciences announces updated TearCare System Indications for Use
TipRanks · 08/19 11:35
More
Webull provides a variety of real-time SGHT stock news. You can receive the latest news about Sight Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.